drugset
drugset / Trial / NCT04070079

Tenofovir Alafenamide With Fine Needle Aspiration Biopsy in Chronic Hepatitis B:

NCT04070079 ↗

Phase 4 Unknown 15 enrolled University Health Network, Toronto
NaSingle-groupOpen-labelTreatment

Summary

The objective of this study is to identify immunological mechanisms that contribute to normalization of liver inflammation in chronic hepatitis B (CHB) patients starting the antiviral nucleoside analogue, Tenofovir alafenamide (TAF).

Timeline

Start
2019-01-29
Primary completion
2022-08-30
Completion
2022-12-31

Drugs

EvaluationDrugModalityDoseRoute
Subject tenofovir alafenamide Small molecule 25 mg Oral

Indications

chronic hepatitis B virus infection